Cadila Healthcare strengthens on the bourses

04 Jun 2018 Evaluate

Cadila Healthcare is currently trading at Rs. 356.65, up by 2.85 points or 0.81% from its previous closing of Rs. 353.80 on the BSE.

The scrip opened at Rs. 357.05 and has touched a high and low of Rs. 359.85 and Rs. 354.40 respectively. So far 10273 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 558.00 on 12-Jun-2017 and a 52 week low of Rs. 341.65 on 22-May-2018.

Last one week high and low of the scrip stood at Rs. 389.55 and Rs. 353.05 respectively. The current market cap of the company is Rs. 36220.01 crore.

The promoters holding in the company stood at 74.79%, while Institutions and Non-Institutions held 16.64% and 8.40% respectively.

Zydus Cadila has received final approval from US Food and Drug Administration (USFDA), to market Doxycycline Hyclate Capsules USP, 50 mg and 100mg. It is a tetracycline antibiotic used for treatment of a wide variety of bacterial infections, including those that cause acne. This medication is also used for prophylaxis of malaria.

It will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad. The group has now more than 195 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Zydus Lifesciences Share Price

988.00 34.40 (3.61%)
02-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1520.00
Dr. Reddys Lab 6260.00
Cipla 1419.55
Zydus Lifesciences 988.00
Lupin 1647.75
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.